Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.